抗感染症ワクチン市場レポート：2022-2032

Anti-infective Vaccines Market Report 2022-2032

レポート詳細抗感染症ワクチン市場レポート 2022-2032 :本レポートは、新たな収益の柱を目指すリーディングカンパニーが、業界とその背景にあるダイナミクスをより深く理解する上で、非常に有益なも... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
Visiongain ヴィジョンゲイン社	2022年8月30日	GBP4,500 部署ライセンスライセンス・価格情報注文方法はこちら	270	278	英語

※上記価格は部署ライセンス（Departmental licence）価格です。
その他の価格についてはデータリソースまでお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

サマリー

レポート詳細

抗感染症ワクチン市場レポート 2022-2032:本レポートは、新たな収益の柱を目指すリーディングカンパニーが、業界とその背景にあるダイナミクスをより深く理解する上で、非常に有益なものとなるでしょう。また、異業種への進出や新地域での既存事業の拡大を目指す企業にとっても有用なレポートです。

感染症の増加により、2032年までの市場成長が見込まれる
感染症の多くは、社会的・経済的な負担を強いるものです。例えば、インフルエンザは毎年数百万人が罹患し、生産性の低下や経済的損失をもたらしています。さらに、毎年、20万人もの人々がインフルエンザによって入院しています。インフルエンザは、医療費と行政の負担につながる重大な感染症として、政府もその重大性を認識せざるを得なくなっています。

また、肝炎、肺炎球菌、髄膜炎など、ワクチン接種で回避できる感染症も同様です。若者や高齢者、そして経済を牽引する働き盛りの人々の接種率を高めるために、各自治体は接種プログラムの拡充を戦略的に進めています。例えばインドでは、国連国際児童基金（UNICEF）が保健家族福祉省（MoHFW）と連携し、インド全域で予防接種の接種率を向上させる予定です。

治療用ワクチンの研究開発が画期的な発見をもたらす
治療用ワクチンの研究開発は、画期的な発見をもたらし、まだ満たされていない医療需要を満たすことになります。その結果、さらに新しいワクチン開発技術が生まれるでしょう。新しい標的部位、免疫反応を誘発する戦略、送達技術など、すべてが研究され、場合によっては成功裏に実施されます。企業はライバルに対して競争優位に立つための革新的な方法を探しており、それは単に時代遅れの予防接種を実施する新しい方法であるかもしれませんが、市場の成長を後押しするでしょう。

ヒト用ワクチン産業にとって大きな問題は、ワクチン製造にかかる費用です。ワクチンの開発には多大な専門知識と労力が必要です。ワクチンは、商品化されるまでに多くの試験段階や規制当局の承認など、長い開発プロセスを経なければなりません。このことから、メーカーにとって、市場規模が大きく、利益を上げられるワクチンを作ることは最優先事項であると言えます。長期的には、ワクチンの有効性と品質を損なうことなく価格を下げるための業界構造改革が重要であり、これは今後も続く問題であると考えられます。

マーケットリサーチレポートを購入する前に、どのような質問をすべきでしょうか？
- 抗感染症ワクチン市場はどのように進化しているのか？
- 抗感染症ワクチン市場の促進要因と抑制要因は？
- 各抗感染症ワクチンのサブマーケット区分は予測期間中にどのように成長し、2032年にはどの程度の売上を占めるようになるのか？
- 2022年から2032年にかけて、各抗感染症ワクチンの市場シェアはどのように推移するのでしょうか？
- 2022年から2032年にかけて、市場全体の主なドライバーは何になるのか？
- 抗感染症ワクチンの主要市場はマクロ経済ダイナミクスに概ね追随するのか、それとも各国市場が他を凌駕するのか？
- 2032年までに各国市場のシェアはどのように変化し、どの地域が2032年の市場をリードするのでしょうか？
- 主要プレイヤーは誰か、また予測期間中の展望は？
- これらの主要企業の抗感染症ワクチンプロジェクトはどのようなものなのか？
- 2020年から2032年の間に、業界はどのように進化していくのか？現在および今後10年間に行われる抗感染症ワクチンのプロジェクトにはどのような意味があるのでしょうか？
- 抗感染症ワクチン市場をさらに拡大するために、製品の商業化の必要性は高まっているのでしょうか？
- 抗感染症ワクチン市場はどこへ向かい、どのようにすれば市場の最前線に立つことができるのでしょうか？
- 新製品やサービスラインに対する最適な投資オプションは何か？
- 企業を新たな成長軌道に乗せ、C-suiteに移行させるための重要な展望とは？

このことが抗感染症ワクチン市場に現在、そして今後10年間、どのような影響を与えるかを知る必要があります。

- 本レポートは270ページにわたり、108の表と170のグラフを掲載しています。
- このレポートでは、業界における主要な収益性の高い分野をハイライトしているため、今すぐターゲットを絞ることができます。
- 世界、地域、国別の売上高と成長率を詳細に分析しています。
- 競合他社が成功した主なトレンド、変化、収益予測をハイライトしています。

本レポートは、抗感染症ワクチン市場が今後10年間にどのように発展し、COVID-19の景気後退と回復の変動に沿うものであるのかを教えてくれます。この市場は、過去10年間のどの時点よりも今が重要なのです。

レポートでは、COVID-19のバリエーションや経済データなど、お客様の市場に特化した独自の情報をお届けしています。

2032年までの予測やその他の分析により、商業的な展望が見えてくる
- 2032年までの収益予測に加え、直近の実績、成長率、市場シェアもご覧いただけます。
- ビジネスの展望や展開など、独自の分析もご覧いただけます。
- 定性的分析（市場力学、促進要因、機会、阻害要因、課題など）、コスト構造、抗感染症ワクチン価格上昇の影響、最近の動向などをご覧いただけます。

本レポートでは、COVID-19が業界と貴社にどのような影響を与えるかについて、データ分析と貴重な洞察を掲載しています。本レポートでは、COVID-19の4つの回収パターンとその影響、すなわち「V」、「L」、「W」、「U」について論じています。

報告書の対象セグメント

疾患タイプ別
・細菌性疾患
- 腸チフスワクチン
- 結核ワクチン
- 破傷風・ジフテリアワクチン
- その他
・ウイルス性疾患
- インフルエンザ・ワクチン
- 肝炎ワクチン
- ポリオワクチン
- その他

製品別
- 生ワクチン/弱毒性ワクチン
- 不活化ワクチン
- DNA/組み換えベクターワクチン
- その他

流通チャネル別
- 病院薬局
- 小売店薬局
- その他

世界市場全体およびセグメントの収益予測に加え、4地域および20の主要国市場の収益予測も掲載しています。

北米
- 米国
- カナダ

欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- ロシア
- その他の欧州地域

アジア太平洋
- 中国
- 日本
- インド
- オーストラリア
- その他のアジア太平洋地域

ラテンアメリカ
- ブラジル
- メキシコ
- その他のラテンアメリカ地域

MEA
- GCC
- 南アフリカ
-その他のMEA地域

抗感染症ワクチン市場の主要企業のプロファイルと2022年から2032年までの、これらの企業のこのセグメントに焦点を当てた情報も掲載しています。

主要企業と市場成長の可能性
・ AstraZeneca
・ Bavarian Nordic
・ BioDiem
・ CSL Limited
・ Emergent BioSolutions Inc.
・ Evotec
・ Merck ＆ Co, Inc.
・ Mitsubishi Tanabe Pharma Corporation
・ Pfizer
・ Serum Institute of India Pvt. Ltd.
・ Sinovac Biotech Ltd.
・ Valneva SE

抗感染症ワクチン市場の世界全体収益、金額ベースで2022年から2032年まで、市場は2022年に579億米ドルを超えると、我々の仕事は計算しています。また、2032年までの間に大幅な売上増を見込んでいます。本調査では、最も大きな可能性を秘めた企業を特定しました。彼らの能力、進歩、商業的展望を知ることで、一歩先を行くことができます。

抗感染症ワクチン市場、2022年から2032年までのレポートはどのように役立つのでしょうか？
270ページを超えるレポートでは、要約すると以下のような知識を得ることができます。

- 抗感染性ワクチン市場の2032年までの収益予測、疾患タイプ、製品、流通チャネルごとに世界と地域レベルでそれぞれ予測 - 業界の展望を発見し、投資と収益に最も有利な場所を見つける。

- 5つの地域と20の主要国市場の2032年までの収益予測 - 北米、欧州、アジア太平洋、LAMEAの抗感染性ワクチン市場、2022年から2032年までの市場予測をご覧いただけます。また、米国、カナダ、メキシコ、ブラジル、ドイツ、フランス、英国、イタリア、中国、インド、日本、オーストラリアなど、著名な経済圏の市場も予測しています。

- 既存企業および市場参入を目指す企業の展望 - 抗感染性ワクチン市場に関与する主要企業12社の企業プロファイルを含む、2022年から2032年までの展望。

定量的・定性的な分析と独自の予測をご覧いただけます。私たちのレポートだけが持つ情報を入手し、貴重なビジネスインテリジェンスを得ることができます。

他にはない情報
私たちの新しいレポートがあれば、知識の遅れを取り戻し、チャンスを逃す可能性が低くなります。私たちの研究が貴社の調査、分析、意思決定にどのように役立つかをご覧ください。Visiongainの調査は、抗感染性ワクチン市場、2022年から2032年、市場をリードする企業のための商業分析を必要とするすべての人のためのものです。データ、トレンド、予測をご覧いただけます。

ページTOPに戻る

1.レポートの概要
1.1 研究の目的
1.2 抗感染症ワクチン市場の紹介
1.3 本レポートが提供するもの
1.4 本レポートを読むべき理由
1.5 本分析レポートが回答する主な質問には以下が含まれる。
1.6 本レポートは誰のためのものか？
1.7 方法論
1.7.1 市場の定義
1.7.2 市場評価・予測手法
1.7.3 データの検証
1.7.3.1 一次調査
1.7.3.2 セカンダリーリサーチ
1.8 よくある質問（FAQ)
1.9 関連するVisiongainのレポート
1.10 Visiongainについて

2 エグゼクティブサマリー

3 市場の概要
3.1 主要な調査結果
3.2 マーケットダイナミクス
3.3 市場の推進要因
3.3.1 予防接種プログラムへの注目の高まりと政府支援
3.3.2 ワクチン開発への投資の増加
3.3.3 ワクチンR＆D強化に向けた企業の取り組み強化
3.3.4 高い感染症罹患率
3.3.5 ワクチン投与における技術的進歩
3.3.6 堅実なR&Dに裏打ちされた強力な供給が市場を牽引
3.4 市場の抑制要因
3.4.1 不十分な保険償還範囲
3.4.2 高いワクチン開発コスト
3.4.3 ワクチン製造の長期化はワクチン市場の成長を阻害する
3.4.4 承認のための厳しい政府規制
3.4.5 ワクチンへの不十分なアクセス
3.5 世界市場における機会
3.5.1 新興国における高い成長見通し
3.5.2 治療用ワクチンへの注目
3.5.3 ワクチンにおけるアジュバントの使用
3.5.4 将来のワクチンR＆Dに対する政府の支援
3.6 COVID-19インパクト分析
3.7 ポーターのファイブフォース分析
3.7.1 バイヤーの交渉力。低～中
3.7.2 供給者の交渉力：低〜中高い
3.7.3 競争相手との競合。低から中
3.7.4 新規参入の脅威:低〜中
3.7.5 代替品の脅威。低
3.8 PEST分析

4 世界の抗感染症ワクチン市場分析：疾患タイプ別
4.1 主な調査結果
4.2 疾患タイプ別成長展望
4.3 抗感染症ワクチンの世界市場規模予測・疾患タイプ別予測
4.4 細菌性疾患
4.4.1 地域別市場予測、2022-2032年 (US$ Mn)
4.4.2 地域別市場シェア、2022年＆2032年(%)
4.5 ウイルス性疾患
4.5.1 地域別市場予測、2022年～2032年(US$ Mn)
4.5.2 地域別市場シェア、2022年＆2032年(%)

5 世界の抗感染症ワクチン市場分析：製品別
5.1 主な調査結果
5.2 製品セグメント別の成長展望
5.3 抗感染症ワクチンの世界製品別市場規模の推定と予測
5.4 生体/弱毒性ワクチン
5.4.1 地域別市場予測、2022年～2032年 (US$ Mn)
5.4.2 地域別市場シェア、2022年＆2032年(%)
5.5 不活性化ワクチン
5.5.1 地域別市場予測、2022年～2032年 (US$ Mn)
5.5.2 地域別市場シェア、2022年＆2032年(%)
5.6 DNA・組換えベクターワクチン
5.6.1 地域別市場予測、2022年～2032年 (US$ Mn)
5.6.2 地域別市場シェア、2022年＆2032年(%)
5.7 その他
5.7.1 地域別市場予測、2022年〜2032年 (US＄ Mn)
5.7.2 地域別市場シェア、2022年＆2032年(%)

6 世界の抗感染症ワクチン市場分析：流通チャネル別
6.1 主な調査結果
6.2 流通チャネル別成長展望
6.3 抗感染症ワクチンの世界市場流通チャネル別市場規模推定・予測
6.4 病院内薬局
6.4.1 地域別市場予測、2022年～2032年 (US$ Mn)
6.4.2 地域別市場シェア、2022年＆2032年(%)
6.5 小売薬局
6.5.1 地域別市場予測、2022年～2032年 (US$ Mn)
6.5.2 地域別市場シェア、2022年＆2032年(%)
6.6 その他
6.6.1 地域別市場予測、2022年〜2032年 (US$ Mn)
6.6.2 地域別市場シェア、2022年＆2032年(%)

7 世界の抗感染症ワクチン市場分析：地域別
7.1 主要な調査結果
7.2 地域別市場規模の推定と予測
7.3 COVID-19のインパクト分析。回復シナリオ(V, U, W, L)

8 北米の抗感染症ワクチン市場分析
8.1 主な調査結果
8.2 北米の抗感染症ワクチン市場の魅力度指数
8.3 国別市場規模、2022年、2027年＆2032年（US$Mn）（単位：百万円）
8.4 国別市場規模推計・予測、2022年～2032年（US$ Mn）
8.5 疾患タイプ別市場規模推定・予測、2022年～2032年（US$ Mn)
8.5.1 細菌性疾患別の市場規模予測・予想
8.5.2 ウイルス性疾患別の市場規模予測・予想
8.6 製品別市場規模予測・予測：2022年〜2032年（US$ Mn）
8.7 流通チャネル別市場規模予測・予測、2022年〜2032年 (US$ Mn)
8.8 国別市場規模予測・予測、2022年～2032年（US$ Mn)
8.8.1 米国
8.8.2 カナダ

9 欧州の抗感染症ワクチン市場分析
9.1 主な調査結果
9.2 欧州の抗感染症ワクチン市場の魅力度指数
9.3 国別市場規模、2022年、2027年＆2032年（US$Mn）（単位：百万円）
9.4 国別市場規模推計・予測、2022年～2032年（US$ Mn)
9.5 疾患タイプ別市場規模推定・予測、2022年～2032年（US$ Mn)
9.5.1 細菌性疾患別の市場規模予測・予想
9.5.2 ウイルス性疾患別の市場規模予測・予想
9.6 製品別市場規模予測・予測：2022年〜2032年（US$ Mn）
9.7 流通チャネル別市場規模予測・予測、2022年〜2032年 (US$ Mn)
9.8 国別市場規模予測・予測、2022年～2032年（US$ Mn）
9.8.1 ドイツ
9.8.2 イギリス
9.8.3 フランス
9.8.4 イタリア
9.8.5 スペイン
9.8.6 ロシア
9.8.7 その他欧州地域

10 アジア太平洋地域の抗感染症ワクチン市場分析
10.1 主な調査結果
10.2 アジア太平洋地域の抗感染症ワクチン市場の魅力度指数
10.3 国別市場規模、2022年、2027年＆2032年（US$Mn）（単位：百万円）
10.4 国別市場規模推計・予測、2022年～2032年（US$ Mn)
10.5 疾患タイプ別市場規模推定・予測、2022年～2032年（US$ Mn)
10.5.1 細菌性疾患別の市場規模予測・予想
10.5.2 ウイルス性疾患別の市場規模予測・予想
10.6 製品別市場規模予測・予測：2022年〜2032年（US$ Mn）
10.7 流通チャネル別市場規模予測・予測、2022年〜2032年 (US$ Mn)
10.8 国別市場規模予測・予測、2022年～2032年（US$ Mn）
10.8.1 日本
10.8.2 中国
10.8.3 インド
10.8.4 オーストラリア
10.8.5 その他のアジア太平洋地域

11 ラテンアメリカの抗感染症ワクチン市場分析
11.1 主要な調査結果
11.2 ラテンアメリカの抗感染症ワクチン市場魅力度指数
11.3 国別市場規模、2022年、2027年＆2032年（US$Mn）（単位：百万円）
11.4 国別市場規模予測・予測、2022年～2032年（US$ Mn)
11.5 疾患タイプ別市場規模推定・予測、2022年～2032年（US$ Mn)
11.5.1 細菌性疾患別の市場規模予測・予想
11.5.2 ウイルス性疾患別の市場規模予測・予想
11.6 製品別市場規模予測・予測：2022年〜2032年（US$ Mn）
11.7 流通チャネル別市場規模予測・予測、2022年〜2032年 (US$ Mn)
11.8 国別市場規模予測・予測、2022年～2032年（US$ Mn）
11.8.1 ブラジル
11.8.2 メキシコ
11.8.3 その他のラテンアメリカ地域

12 MEAの抗感染症ワクチン市場分析
12.1 主要な調査結果
12.2 MEA抗感染症ワクチン市場の魅力度指数
12.3 国別市場規模、2022年、2027年＆2032年 (US$Mn)(単位：百万円)
12.4 国別市場規模予測・予測、2022年～2032年（US$ Mn)
12.5 疾患タイプ別市場規模推定・予測、2022年～2032年（US$ Mn）
12.5.1 細菌性疾患別の市場規模予測・予想
12.5.2 ウイルス性疾患別の市場規模予測・予想
12.6 製品別市場規模予測・予測：2022年〜2032年（US$ Mn）
12.7 流通チャネル別市場規模予測・予測、2022年〜2032年 (US$ Mn)
12.8 国別市場規模予測・予測、2022年～2032年（US$ Mn)
12.8.1 GCC
12.8.2 南アフリカ
12.8.3 その他のMEA地域

13 主要企業のプロフィール
13.1 アストラゼネカPLC
13.1.1 企業スナップショット
13.1.2 会社概要
13.1.3 財務分析
13.1.3.1 純収益、2016-2021年
13.1.3.2 地域別市場シェア、2021年
13.1.3.3 売上総利益、2016年～2021年
13.1.3.4 R＆D、2016-2021年
13.1.4 製品ベンチマーク
13.1.5 戦略的な展望
13.2 バイエルン・ノルディック
13.2.1 企業スナップショット
13.2.2 会社概要
13.2.3 財務分析
13.2.3.1 純収益、2016-2021年
13.2.3.2 地域別市場シェア、2021年
13.2.3.3 売上総利益、2016年～2021年
13.2.3.4 R＆D、2016-2021年
13.2.4 製品ベンチマーク
13.2.5 戦略的な展望
13.3 バイオディエム
13.3.1 企業スナップショット
13.3.2 会社概要
13.3.3 財務分析
13.3.4 製品ベンチマーク
13.3.5 戦略的展望
13.4 CSLリミテッド
13.4.1 企業スナップショット
13.4.2 会社概要
13.4.3 財務分析
13.4.3.1 純収益、2016-2021年
13.4.3.2 地域別市場シェア、2021年
13.4.3.3 売上総利益、2016年～2021年
13.4.3.4 R＆D、2016-2021年
13.4.4 製品ベンチマーク
13.4.5 戦略的な展望
13.5 エマージェント・バイオソリューションズ社
13.5.1 企業スナップショット
13.5.2 会社概要
13.5.3 財務分析
13.5.3.1 純収益、2016-2021年
13.5.3.2 売上総利益、2016年-2021年
13.5.3.3 R＆D、2016-2021年
13.5.4 製品ベンチマーク
13.5.5 戦略的な展望
13.6 エボテック
13.6.1 企業スナップショット
13.6.2 会社概要
13.6.3 財務分析
13.6.3.1 純収益、2016-2021年
13.6.3.2 地域別市場シェア、2021年
13.6.3.3 売上総利益、2016年-2021年
13.6.3.4 R＆D、2016-2021年
13.6.4 製品ベンチマーク
13.6.5 戦略的な展望
13.7 Merck & Co, Inc.
13.7.1 企業スナップショット
13.7.2 会社概要
13.7.3 財務分析
13.7.3.1 純収益、2016-2021年
13.7.3.2 地域別市場シェア、2021年
13.7.3.3 売上総利益、2016年-2021年
13.7.3.4 R＆D、2016-2021年
13.7.4 製品ベンチマーク
13.7.5 戦略的展望
13.8 田辺三菱製薬株式会社
13.8.1 企業スナップショット
13.8.2 会社概要
13.8.3 ベンチマーキング
13.8.4 戦略的展望
13.9 ファイザー
13.9.1 企業スナップショット
13.9.2 会社概要
13.9.3 財務分析
13.9.3.1 純収益、2016-2021年
13.9.3.2 地域別市場シェア、2021年
13.9.3.3 売上総利益、2016年-2021年
13.9.3.4 R＆D、2016-2021年
13.9.4 製品ベンチマーク
13.9.5 戦略的な展望
13.10 Serum Institute of India Pvt.Ltd.
13.10.1 企業スナップショット
13.10.2 会社概要
13.10.3 製品ベンチマーク
13.10.4 戦略的展望
13.11 シノヴァック・バイオテック
13.11.1 企業スナップショット
13.11.2 会社概要
13.11.3 財務分析
13.11.3.1 純収益、2016-2021年
13.11.3.2 売上総利益、2016年-2021年
13.11.3.3 R＆D、2016-2021年
13.11.4 製品ベンチマーク
13.12 ヴァルネバSE
13.12.1 企業スナップショット
13.12.2 会社概要
13.12.3 財務分析
13.12.3.1 純収益、2016-2021年
13.12.4 製品ベンチマーク
13.12.5 戦略的展望

14 結論と提言
14.1 ビジョンゲインからの結論
14.2 市場関係者への提言

表の一覧
Table 1 Global Anti-infective Vaccines Market Snapshot, 2022 & 2032 (US$ billion, CAGR %)
Table 2 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 3 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 4 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 5 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 6 Global Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 7 Bacterial Diseases Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 8 Viral Diseases Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 9 Global Anti-infective Vaccines Market Forecast by Product Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 10 Live/Attenuated Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 11 Major Whole Inactivated Virus COVID-19 Vaccine
Table 12 Inactivated Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 13 DNA Vaccines for Global COVID-19: Global Status
Table 14 DNA & Recombinant Vector Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 15 Others Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 16 Global Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million, AGR%, CAGR %)
Table 17 Hospital Pharmacy Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 18 Retail Pharmacy Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 19 Others Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 20 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 21 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 22 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 23 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 24 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 25 North America Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 26 North America Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 27 North America Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 28 North America Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 29 North America Anti-infective Vaccines Market Forecast by Product Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 30 North America Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million, AGR%, CAGR %)
Table 31 U.S Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 32 Canada Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 33 Europe Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 34 Europe Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 35 Europe Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 36 Europe Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 37 Europe Anti-infective Vaccines Market Forecast by Product Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 38 Europe Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million, AGR%, CAGR %)
Table 39 Germany Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 40 UK Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 41 France Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 42 Italy Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 43 Spain Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 44 Russia Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 45 Rest of Europe Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 46 Asia Pacific Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 47 Asia Pacific Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 48 Asia Pacific Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 49 Asia Pacific Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 50 Asia Pacific Anti-infective Vaccines Market Forecast by Product Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 51 Asia Pacific Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million, AGR%, CAGR %)
Table 52 Japan Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 53 China Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 54 India Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 55 Australia Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 56 Rest of Asia Pacific Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 57 Latin America Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 58 Latin America Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 59 Latin America Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 60 Latin America Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 61 Latin America Anti-infective Vaccines Market Forecast by Product Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 62 Latin America Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million, AGR%, CAGR %)
Table 63 Brazil Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 64 Mexico Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 65 Rest of Latin America Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 66 MEA Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 67 MEA Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 68 MEA Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 69 MEA Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 70 MEA Anti-infective Vaccines Market Forecast by Product Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 71 MEA Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million, AGR%, CAGR %)
Table 72 GCC Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 73 South Africa Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 74 MEA Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 75 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 76 AstraZeneca: Product Benchmarking
Table 77 AstraZeneca: Strategic Outlook
Table 78 Bavarian Nordic: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 Bavarian Nordic: Product Benchmarking
Table 80 Bavarian Nordic: Strategic Outlook
Table 81 BioDiem: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 BioDiem: Product Benchmarking
Table 83 CSL Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 84 CSL Limited: Product Benchmarking
Table 85 CSL Limited: Strategic Outlook
Table 86 Emergent BioSolutions Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 Emergent BioSolutions Inc.: Product Benchmarking
Table 88 Emergent BioSolutions Inc.: Strategic Outlook
Table 89 Evotec: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 Evotec: Product Benchmarking
Table 91 Evotec: Strategic Outlook
Table 92 Merck & Co, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 Merck & Co, Inc.: Product Benchmarking
Table 94 Merck & Co, Inc.: Strategic Outlook
Table 95 Mitsubishi Tanabe Pharma Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 Mitsubishi Tanabe Pharma Corporation: Product Benchmarking
Table 97 Mitsubishi Tanabe Pharma Corporation: Strategic Outlook
Table 98 Pfizer: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Pfizer: Product Benchmarking
Table 100 Pfizer: Strategic Outlook
Table 101 Serum Institute of India Pvt. Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 Serum Institute of India Pvt. Ltd.: Product Benchmarking
Table 103 Serum Institute of India Pvt. Ltd.: Strategic Outlook
Table 104 Sinovac Biotech Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Sinovac Biotech Ltd.: Product Benchmarking
Table 106 Valneva SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Valneva SE: Product Benchmarking
Table 108 Valneva SE: Strategic Outlook

図の一覧
Figure 1 Global Anti-infective Vaccines Market Segmentation
Figure 2 Global Anti-infective Vaccines Market Attractiveness Index by Region
Figure 3 Global Anti-infective Vaccines Market by Disease Type: Market Attractiveness Index
Figure 4 Global Anti-infective Vaccines Market by Product: Market Attractiveness Index
Figure 5 Global Anti-infective Vaccines Market by Distribution Channel: Market Attractiveness Index
Figure 6 Global Anti-infective Vaccines Market: Market Dynamics
Figure 7 Global COVID Impact Analysis: Anti-infective Vaccines Market Recovery Scenarios
Figure 8 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 9 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 10 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 11 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 12 Global Anti-infective Vaccines Market: Porter’s Five Forces Analysis
Figure 13 Global Anti-infective Vaccines Market: PEST Analysis
Figure 14 Global Anti-infective Vaccines Market Attractiveness Index by Disease Type
Figure 15 Global Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million)
Figure 16 Global Anti-infective Vaccines Market Share Forecast by Disease Type, 2022, 2027, 2032 (%)
Figure 17 Bacterial Diseases Market Forecast by Region, 2022-2032 (US$ million)
Figure 18 Bacterial Diseases Market Share Forecast by Region, 2022 & 2032 (%)
Figure 19 Viral Diseases Market Forecast by Region, 2022-2032 (US$ million)
Figure 20 Viral Diseases Market Share Forecast by Region, 2022 & 2032 (%)
Figure 21 Global Anti-infective Vaccines Market Attractiveness Index by Disease Type
Figure 22 Global Anti-infective Vaccines Market Forecast by Product, 2022-2032 (US$ million)
Figure 23 Global Anti-infective Vaccines Market Share Forecast by Product, 2022, 2027, 2032 (%)
Figure 24 Live/Attenuated Vaccines Market Forecast by Region, 2022-2032 (US$ million)
Figure 25 Live/Attenuated Vaccines Market Share Forecast by Region, 2022 & 2032 (%)
Figure 26 Inactivated Vaccines Market Forecast by Region, 2022-2032 (US$ million)
Figure 27 Inactivated Vaccines Market Share Forecast by Region, 2022 & 2032 (%)
Figure 28 DNA & Recombinant Vector Vaccines Market Forecast by Region, 2022-2032 (US$ million)
Figure 29 DNA & Recombinant Vector Vaccines Market Share Forecast by Region, 2022 & 2032 (%)
Figure 30 Others Market Forecast by Region, 2022-2032 (US$ million)
Figure 31 Others Market Share Forecast by Region, 2022 & 2032 (%)
Figure 32 Global Anti-infective Vaccines Market Attractiveness Index by Distribution Channel
Figure 33 Global Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million)
Figure 34 Global Anti-infective Vaccines Market Share Forecast by Distribution Channel, 2022, 2027, 2032 (%)
Figure 35 Hospital Pharmacy Market Forecast by Region, 2022-2032 (US$ million)
Figure 36 Hospital Pharmacy Market Share Forecast by Region, 2022 & 2032 (%)
Figure 37 Retail Pharmacy Market Forecast by Region, 2022-2032 (US$ million)
Figure 38 Retail Pharmacy Market Share Forecast by Region, 2022 & 2032 (%)
Figure 39 Others Market Forecast by Region, 2022-2032 (US$ million)
Figure 40 Others Market Share Forecast by Region, 2022 & 2032 (%)
Figure 41 Global Anti-infective Vaccines Market Forecast by Region 2022, 2027, 2032 (Revenue, CAGR %)
Figure 42 Global Anti-infective Vaccines Market Share Forecast by Region 2022, 2027, 2032(%)
Figure 43 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Figure 44 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 45 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 46 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 47 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 48 North America Anti-infective Vaccines Market Attractiveness Index
Figure 49 North America Anti-infective Vaccines Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 50 North America Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million)
Figure 51 North America Anti-infective Vaccines Market Share Forecast by Country, 2022 & 2032 (%)
Figure 52 North America Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million)
Figure 53 North America Anti-infective Vaccines Market Share Forecast by Disease Type, 2022 & 2032 (%)
Figure 54 North America Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million)
Figure 55 North America Anti-infective Vaccines Market Share Forecast by Bacterial Diseases, 2022 & 2032 (%)
Figure 56 North America Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million)
Figure 57 North America Anti-infective Vaccines Market Share Forecast by Viral Diseases, 2022 & 2032 (%)
Figure 58 North America Anti-infective Vaccines Market Forecast by Product, 2022-2032 (US$ million)
Figure 59 North America Anti-infective Vaccines Market Share Forecast by Product, 2022 & 2032 (%)
Figure 60 North America Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million)
Figure 61 North America Anti-infective Vaccines Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 62 U.S. Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 63 Canada Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 64 Europe Anti-infective Vaccines Market Attractiveness Index
Figure 65 Europe Anti-infective Vaccines Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 66 Europe Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million)
Figure 67 Europe Anti-infective Vaccines Market Share Forecast by Country, 2022 & 2032 (%)
Figure 68 Europe Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million)
Figure 69 Europe Anti-infective Vaccines Market Share Forecast by Disease Type, 2022 & 2032 (%)
Figure 70 Europe Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million)
Figure 71 Europe Anti-infective Vaccines Market Share Forecast by Bacterial Diseases, 2022 & 2032 (%)
Figure 72 Europe Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million)
Figure 73 Europe Anti-infective Vaccines Market Share Forecast by Viral Diseases, 2022 & 2032 (%)
Figure 74 Europe Anti-infective Vaccines Market Forecast by Product, 2022-2032 (US$ million)
Figure 75 Europe Anti-infective Vaccines Market Share Forecast by Product, 2022 & 2032 (%)
Figure 76 Europe Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million)
Figure 77 Europe Anti-infective Vaccines Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 78 Germany Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 79 UK Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 80 France Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 81 Italy Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 82 Spain Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 83 Russia Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 84 Rest of Europe Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 85 Asia Pacific Anti-infective Vaccines Market Attractiveness Index
Figure 86 Asia Pacific Anti-infective Vaccines Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 87 Asia Pacific Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million)
Figure 88 Asia Pacific Anti-infective Vaccines Market Share Forecast by Country, 2022 & 2032 (%)
Figure 89 Asia Pacific Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million)
Figure 90 Asia Pacific Anti-infective Vaccines Market Share Forecast by Disease Type, 2022 & 2032 (%)
Figure 91 Asia Pacific Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million)
Figure 92 Asia Pacific Anti-infective Vaccines Market Share Forecast by Bacterial Diseases, 2022 & 2032 (%)
Figure 93 Asia Pacific Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million)
Figure 94 Asia Pacific Anti-infective Vaccines Market Share Forecast by Viral Diseases, 2022 & 2032 (%)
Figure 95 Asia Pacific Anti-infective Vaccines Market Forecast by Product, 2022-2032 (US$ million)
Figure 96 Asia Pacific Anti-infective Vaccines Market Share Forecast by Product, 2022 & 2032 (%)
Figure 97 Asia Pacific Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million)
Figure 98 Asia Pacific Anti-infective Vaccines Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 99 Japan Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 100 China Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 101 India Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 102 Australia Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 103 Rest of Asia Pacific Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 104 Latin America Anti-infective Vaccines Market Attractiveness Index
Figure 105 Latin America Anti-infective Vaccines Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 106 Latin America Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million)
Figure 107 Latin America Anti-infective Vaccines Market Share Forecast by Country, 2022 & 2032 (%)
Figure 108 Latin America Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million)
Figure 109 Latin America Anti-infective Vaccines Market Share Forecast by Disease Type, 2022 & 2032 (%)
Figure 110 Latin America Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million)
Figure 111 Latin America Anti-infective Vaccines Market Share Forecast by Bacterial Diseases, 2022 & 2032 (%)
Figure 112 Latin America Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million)
Figure 113 Latin America Anti-infective Vaccines Market Share Forecast by Viral Diseases, 2022 & 2032 (%)
Figure 114 Latin America Anti-infective Vaccines Market Forecast by Product, 2022-2032 (US$ million)
Figure 115 Latin America Anti-infective Vaccines Market Share Forecast by Product, 2022 & 2032 (%)
Figure 116 Latin America Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million)
Figure 117 Latin America Anti-infective Vaccines Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 118 Brazil Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 119 Mexico Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 120 Rest of Latin America Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 121 MEA Anti-infective Vaccines Market Attractiveness Index
Figure 122 MEA Anti-infective Vaccines Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 123 MEA Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million)
Figure 124 MEA Anti-infective Vaccines Market Share Forecast by Country, 2022 & 2032 (%)
Figure 125 MEA Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million)
Figure 126 MEA Anti-infective Vaccines Market Share Forecast by Disease Type, 2022 & 2032 (%)
Figure 127 MEA Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million)
Figure 128 MEA Anti-infective Vaccines Market Share Forecast by Bacterial Diseases, 2022 & 2032 (%)
Figure 129 MEA Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million)
Figure 130 MEA Anti-infective Vaccines Market Share Forecast by Viral Diseases, 2022 & 2032 (%)
Figure 131 MEA Anti-infective Vaccines Market Forecast by Product, 2022-2032 (US$ million)
Figure 132 MEA Anti-infective Vaccines Market Share Forecast by Product, 2022 & 2032 (%)
Figure 133 MEA Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million)
Figure 134 MEA Anti-infective Vaccines Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 135 GCC Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 136 South Africa Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 137 Rest of MEA Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 138 AstraZeneca: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 139 AstraZeneca: Regional Market Shares, 2021
Figure 140 AstraZeneca: Gross Profit, 2016-2021 (US$ million, AGR %)
Figure 141 AstraZeneca: R&D, 2016-2021 (US$ million, AGR %)
Figure 142 Bavarian Nordic: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 143 Bavarian Nordic: Regional Market Shares, 2021
Figure 144 Bavarian Nordic: Gross Profit, 2016-2021 (US$ million, AGR %)
Figure 145 Bavarian Nordic: R&D, 2016-2021 (US$ million, AGR %)
Figure 146 CSL Limited: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 147 CSL Limited: Regional Market Shares, 2021
Figure 148 CSL Limited: Gross Profit, 2016-2021 (US$ million, AGR %)
Figure 149 CSL Limited: R&D, 2016-2021 (US$ million, AGR %)
Figure 150 Emergent BioSolutions Inc.: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 151 Emergent BioSolutions Inc.: Gross Profit, 2016-2021 (US$ million, AGR %)
Figure 152 Emergent BioSolutions Inc.: R&D, 2016-2021 (US$ million, AGR %)
Figure 153 Evotec: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 154 Evotec: Regional Market Shares, 2021
Figure 155 Evotec: Gross Profit, 2016-2021 (US$ million, AGR %)
Figure 156 Evotec: R&D, 2016-2021 (US$ million, AGR %)
Figure 157 Merck & Co, Inc.: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 158 Merck & Co, Inc.: Regional Market Shares, 2021
Figure 159 Merck & Co, Inc.: Gross Profit, 2016-2021 (US$ million, AGR %)
Figure 160 Merck & Co, Inc.: R&D, 2016-2021 (US$ million, AGR %)
Figure 161 Pfizer: Net Revenue, 2016-2021 (US$ million, AGR%)
Figure 162 Pfizer: Regional Market Shares, 2021
Figure 163 Pfizer: Gross Profit, 2016-2021 (US$ million, AGR%)
Figure 164 Pfizer: R&D, 2016-2021 (US$ million, AGR%)
Figure 165 Sinovac Biotech Ltd.: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 166 Sinovac Biotech Ltd.: Gross Profit, 2016-2021 (US$ million, AGR %)
Figure 167 Sinovac Biotech Ltd.: R&D, 2016-2021 (US$ million, AGR %)
Figure 168 Valneva SE: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 169 Global Anti-infective Vaccines Market Forecast by Region 2022, 2027, 2032 (Revenue, CAGR %)
Figure 170 Global Anti-infective Vaccines Market Share Forecast by Region 2022, 2027, 2032 (%)

ページTOPに戻る

Table of Contents

Summary

この調査レポートは世界の抗感染症ワクチン市場を調査し、疾患タイプ別、製品別、流通チャネル別、地域別に2022年から2032年までの予測結果を掲載しています。また関連企業情報を提供しています。

主な掲載内容（目次より抜粋）

レポート概要
エグゼクティブサマリー
市場概要
抗感染症ワクチンの世界市場分析：疾患タイプ別
抗感染症ワクチンの世界市場分析：製品別
抗感染症ワクチンの世界市場分析：流通チャネル別
抗感染症ワクチンの世界市場分析：地域別
北米の抗感染症ワクチン市場分析
欧州の抗感染症ワクチン市場分析
アジア太平洋地域の抗感染症ワクチン市場分析
ラテンアメリカの抗感染症ワクチン市場分析
主要企業のプロフィール

Report Details

The Anti-Infective Vaccines Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Growing Burden of Infectious Disease Likely to Boost Market Growth Through 2032
The majority of infectious diseases place a social and financial strain on society. For instance, influenza affects millions of people every year, which leads to decreased productivity and economic losses. Furthermore, each year, up to 200,000 people are hospitalized due to influenza. Governments have been compelled to acknowledge the severity of influenza as a serious infection that leads to healthcare expenses and a burden on government bodies.

The same is true for the various infectious diseases that can be avoided with vaccination, including hepatitis, pneumococcal, and meningitis among other infectious diseases. To enhance vaccination coverage rates among youngsters, the elderly, and the working adults who drive the economy, local governments are strategizing on expanding their vaccination programs. For instance, in India, the United Nations International Children’s Emergency Fund (UNICEF) in collaboration with the Ministry of Health and Family Welfare (MoHFW) will enhance vaccination immunization coverage across the Indian region.

Research and Development on Therapeutic Vaccines will lead to Ground-Breaking Discoveries
Research and development on therapeutic vaccines will lead to ground-breaking discoveries and fill medical demands that have not yet been satisfied. Additional novel vaccine development techniques will result from this. New target sites, strategies for inducing an immune response, and delivery techniques are all being studied and, in some cases, successfully implemented. As businesses look for innovative ways to get a competitive edge over their rivals, which could simply be a new method of administering an outdated immunization mode of delivery will boost the market growth

A major issue for the human vaccine industry is the expense of vaccine production. The development of vaccines requires a great deal of expertise and work. A vaccine must go through a lengthy development process that includes numerous trial phases and regulatory approval before it can be commercialized. This indicates that creating a vaccine with a sizable market and the capacity to make a profit accounts for a top priority for manufacturers. The long-term focus of these manufacturers will be on implementing structural reforms in the industry that can lower prices without compromising vaccine effectiveness and quality because this will continue to be a problem in the years to come.

What Questions Should You Ask before Buying a Market Research Report?
• How is the Anti-Infective Vaccines Market evolving?
• What is driving and restraining the Anti-Infective Vaccines Market?
• How will each Anti-Infective Vaccines submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each Anti-Infective Vaccines submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading Anti-Infective Vaccines markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are The Anti-Infective Vaccines projects for these leading companies?
• How will the industry evolve during the period between 2020 and 2032? What are the implications of anti-infective vaccine projects taking place now and over the next 10 years?
• Is there a greater need for product commercialization to further scale the Anti-Infective Vaccines Market?
• Where is the Anti-Infective Vaccines Market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Anti-Infective Vaccines Market today, and over the next 10 years:
• Our 270-page report provides 108 tables and 170 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Anti-Infective Vaccines Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

The report delivers exclusive COVID-19 variations and economic data specific to your market.

Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising anti-infective vaccines prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Disease Type
• Bacterial Diseases
– Typhoid Vaccines
– Tuberculosis Vaccines
– Tetanus & Diphtheria Vaccines
– Others
• Viral Diseases
– Influenza Vaccines
– Hepatitis Vaccines
– Polio Vaccine
– Others

Product
• Live/Attenuated Vaccines
• Inactivated Vaccines
• DNA & Recombinant Vector Vaccines
• Others

Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 20 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• France
• UK
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Anti-infective Vaccines Market, 2022 to 2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• AstraZeneca
• Bavarian Nordic
• BioDiem
• CSL Limited
• Emergent BioSolutions Inc.
• Evotec
• Merck & Co, Inc.
• Mitsubishi Tanabe Pharma Corporation
• Pfizer
• Serum Institute of India Pvt. Ltd.
• Sinovac Biotech Ltd.
• Valneva SE

Overall world revenue for Anti-infective Vaccines Market, 2022 to 2032 in terms of value the market will surpass US$57.9 billion in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Anti-infective Vaccines Market, 2022 to 2032 report help you?
In summary, our 270+ page report provides you with the following knowledge:

• Revenue forecasts to 2032 for Anti-infective Vaccines Market, 2022 to 2032, with forecasts for disease type, product, and distribution channel each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2032 for five regional and 20 key national markets – See forecasts for the Anti-Infective Vaccines Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the U.S., Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 12 of the major companies involved in the Anti-Infective Vaccines Market, 2022 to 2032.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Anti-Infective Vaccines Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.

ページTOPに戻る

Table of Contents

1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Anti-infective Vaccines Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered By This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Market Driving Factors
3.3.1 Rising Focus and Government Support on Immunization Programs
3.3.2 Growing Investment in Vaccine Development
3.3.3 Increasing Company Initiatives to Enhance Vaccine R&D
3.3.4 High Prevalence of Infectious Diseases
3.3.5 Technological Advancements in Vaccine Administration
3.3.6 Strong Supply Backed Up by Robust R&D to Drive the Market
3.4 Market Restraining Factors
3.4.1 Inadequate Reimbursement Coverage
3.4.2 High Cost of Vaccine Development
3.4.3 Extended Timelines of Vaccine Manufacturing Hinder the Growth of the Vaccines Market
3.4.4 Stringent Government Regulations for Approval
3.4.5 Inadequate Access to Vaccines
3.5 Opportunities in the Global Market
3.5.1 High Growth Prospects in Emerging Markets
3.5.2 Focus on Therapeutic Vaccines
3.5.3 Use of Adjuvants in Vaccines
3.5.4 Government Support for Future Vaccine R&D
3.6 COVID-19 Impact Analysis
3.7 Porter’s Five Forces Analysis
3.7.1 Bargaining Power of Buyers: Low to Medium
3.7.2 Bargaining Power of Suppliers: High
3.7.3 Competitive Rivalry: Low to Medium
3.7.4 Threat of New Entrants: Low to Medium
3.7.5 Threat of Substitutes: Low
3.8 PEST Analysis

4 Global Anti-infective Vaccines Market Analysis by Disease Type
4.1 Key Findings
4.2 Disease Type Segment Growth Prospects
4.3 Global Anti-infective Vaccines Market Size Estimation and Forecast by Disease Type
4.4 Bacterial Diseases
4.4.1 Market Forecast by Region, 2022-2032 (US$ Mn)
4.4.2 Market Share by Region, 2022 & 2032 (%)
4.5 Viral Diseases
4.5.1 Market Forecast by Region, 2022-2032 (US$ Mn)
4.5.2 Market Share by Region, 2022 & 2032 (%)

5 Global Anti-infective Vaccines Market Analysis by Product
5.1 Key Findings
5.2 Product Segment Growth Prospects
5.3 Global Anti-infective Vaccines Market Size Estimation and Forecast by Product
5.4 Live/Attenuated Vaccines
5.4.1 Market Forecast by Region, 2022-2032 (US$ Mn)
5.4.2 Market Share by Region, 2022 & 2032 (%)
5.5 Inactivated Vaccines
5.5.1 Market Forecast by Region, 2022-2032 (US$ Mn)
5.5.2 Market Share by Region, 2022 & 2032 (%)
5.6 DNA & Recombinant Vector Vaccines
5.6.1 Market Forecast by Region, 2022-2032 (US$ Mn)
5.6.2 Market Share by Region, 2022 & 2032 (%)
5.7 Others
5.7.1 Market Forecast by Region, 2022-2032 (US$ Mn)
5.7.2 Market Share by Region, 2022 & 2032 (%)

6 Global Anti-infective Vaccines Market Analysis by Distribution Channel
6.1 Key Findings
6.2 Distribution Channel Segment Growth Prospects
6.3 Global Anti-infective Vaccines Market Size Estimation and Forecast by Distribution Channel
6.4 Hospital Pharmacy
6.4.1 Market Forecast by Region, 2022-2032 (US$ Mn)
6.4.2 Market Share by Region, 2022 & 2032 (%)
6.5 Retail Pharmacy
6.5.1 Market Forecast by Region, 2022-2032 (US$ Mn)
6.5.2 Market Share by Region, 2022 & 2032 (%)
6.6 Others
6.6.1 Market Forecast by Region, 2022-2032 (US$ Mn)
6.6.2 Market Share by Region, 2022 & 2032 (%)

7 Global Anti-infective Vaccines Market Analysis by Region
7.1 Key Findings
7.2 Regional Market Size Estimation and Forecast
7.3 COVID-19 Impact Analysis: Recovery Scenarios (V, U, W, L)

8 North America Anti-infective Vaccines Market Analysis
8.1 Key Findings
8.2 North America Anti-infective Vaccines Market Attractiveness Index
8.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
8.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
8.5 Market Size Estimation and Forecast by Disease Type, 2022-2032 (US$ Mn)
8.5.1 Market Size Estimation and Forecast by Bacterial Diseases
8.5.2 Market Size Estimation and Forecast by Viral Diseases
8.6 Market Size Estimation and Forecast by Product, 2022-2032 (US$ Mn)
8.7 Market Size Estimation and Forecast by Distribution Channel, 2022-2032 (US$ Mn)
8.8 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
8.8.1 U.S.
8.8.2 Canada

9 Europe Anti-infective Vaccines Market Analysis
9.1 Key Findings
9.2 Europe Anti-infective Vaccines Market Attractiveness Index
9.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
9.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
9.5 Market Size Estimation and Forecast by Disease Type, 2022-2032 (US$ Mn)
9.5.1 Market Size Estimation and Forecast by Bacterial Diseases
9.5.2 Market Size Estimation and Forecast by Viral Diseases
9.6 Market Size Estimation and Forecast by Product, 2022-2032 (US$ Mn)
9.7 Market Size Estimation and Forecast by Distribution Channel, 2022-2032 (US$ Mn)
9.8 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
9.8.1 Germany
9.8.2 UK
9.8.3 France
9.8.4 Italy
9.8.5 Spain
9.8.6 Russia
9.8.7 Rest of Europe

10 Asia Pacific Anti-infective Vaccines Market Analysis
10.1 Key Findings
10.2 Asia Pacific Anti-infective Vaccines Market Attractiveness Index
10.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
10.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
10.5 Market Size Estimation and Forecast by Disease Type, 2022-2032 (US$ Mn)
10.5.1 Market Size Estimation and Forecast by Bacterial Diseases
10.5.2 Market Size Estimation and Forecast by Viral Diseases
10.6 Market Size Estimation and Forecast by Product, 2022-2032 (US$ Mn)
10.7 Market Size Estimation and Forecast by Distribution Channel, 2022-2032 (US$ Mn)
10.8 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
10.8.1 Japan
10.8.2 China
10.8.3 India
10.8.4 Australia
10.8.5 Rest of Asia Pacific

11 Latin America Anti-infective Vaccines Market Analysis
11.1 Key Findings
11.2 Latin America Anti-infective Vaccines Market Attractiveness Index
11.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
11.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
11.5 Market Size Estimation and Forecast by Disease Type, 2022-2032 (US$ Mn)
11.5.1 Market Size Estimation and Forecast by Bacterial Diseases
11.5.2 Market Size Estimation and Forecast by Viral Diseases
11.6 Market Size Estimation and Forecast by Product, 2022-2032 (US$ Mn)
11.7 Market Size Estimation and Forecast by Distribution Channel, 2022-2032 (US$ Mn)
11.8 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
11.8.1 Brazil
11.8.2 Mexico
11.8.3 Rest of Latin America

12 MEA Anti-infective Vaccines Market Analysis
12.1 Key Findings
12.2 MEA Anti-infective Vaccines Market Attractiveness Index
12.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
12.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
12.5 Market Size Estimation and Forecast by Disease Type, 2022-2032 (US$ Mn)
12.5.1 Market Size Estimation and Forecast by Bacterial Diseases
12.5.2 Market Size Estimation and Forecast by Viral Diseases
12.6 Market Size Estimation and Forecast by Product, 2022-2032 (US$ Mn)
12.7 Market Size Estimation and Forecast by Distribution Channel, 2022-2032 (US$ Mn)
12.8 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
12.8.1 GCC
12.8.2 South Africa
12.8.3 Rest of MEA

13 Company Profiles
13.1 AstraZeneca PLC.
13.1.1 Company Snapshot
13.1.2 Company Overview
13.1.3 Financial Analysis
13.1.3.1 Net Revenue, 2016-2021
13.1.3.2 Regional Market Shares, 2021
13.1.3.3 Gross Profit, 2016-2021
13.1.3.4 R&D, 2016-2021
13.1.4 Product Benchmarking
13.1.5 Strategic Outlook
13.2 Bavarian Nordic
13.2.1 Company Snapshot
13.2.2 Company Overview
13.2.3 Financial Analysis
13.2.3.1 Net Revenue, 2016-2021
13.2.3.2 Regional Market Shares, 2021
13.2.3.3 Gross Profit, 2016-2021
13.2.3.4 R&D, 2016-2021
13.2.4 Product Benchmarking
13.2.5 Strategic Outlook
13.3 BioDiem
13.3.1 Company Snapshot
13.3.2 Company Overview
13.3.3 Financial Analysis
13.3.4 Product Benchmarking
13.3.5 Strategic Outlook
13.4 CSL Limited
13.4.1 Company Snapshot
13.4.2 Company Overview
13.4.3 Financial Analysis
13.4.3.1 Net Revenue, 2016-2021
13.4.3.2 Regional Market Shares, 2021
13.4.3.3 Gross Profit, 2016-2021
13.4.3.4 R&D, 2016-2021
13.4.4 Product Benchmarking
13.4.5 Strategic Outlook
13.5 Emergent BioSolutions Inc.
13.5.1 Company Snapshot
13.5.2 Company Overview
13.5.3 Financial Analysis
13.5.3.1 Net Revenue, 2016-2021
13.5.3.2 Gross Profit, 2016-2021
13.5.3.3 R&D, 2016-2021
13.5.4 Product Benchmarking
13.5.5 Strategic Outlook
13.6 Evotec
13.6.1 Company Snapshot
13.6.2 Company Overview
13.6.3 Financial Analysis
13.6.3.1 Net Revenue, 2016-2021
13.6.3.2 Regional Market Shares, 2021
13.6.3.3 Gross Profit, 2016-2021
13.6.3.4 R&D, 2016-2021
13.6.4 Product Benchmarking
13.6.5 Strategic Outlook
13.7 Merck & Co, Inc.
13.7.1 Company Snapshot
13.7.2 Company Overview
13.7.3 Financial Analysis
13.7.3.1 Net Revenue, 2016-2021
13.7.3.2 Regional Market Shares, 2021
13.7.3.3 Gross Profit, 2016-2021
13.7.3.4 R&D, 2016-2021
13.7.4 Product Benchmarking
13.7.5 Strategic Outlook
13.8 Mitsubishi Tanabe Pharma Corporation
13.8.1 Company Snapshot
13.8.2 Company Overview
13.8.3 Product Benchmarking
13.8.4 Strategic Outlook
13.9 Pfizer
13.9.1 Company Snapshot
13.9.2 Company Overview
13.9.3 Financial Analysis
13.9.3.1 Net Revenue, 2016-2021
13.9.3.2 Regional Market Shares, 2021
13.9.3.3 Gross Profit, 2016-2021
13.9.3.4 R&D, 2016-2021
13.9.4 Product Benchmarking
13.9.5 Strategic Outlook
13.10 Serum Institute of India Pvt. Ltd.
13.10.1 Company Snapshot
13.10.2 Company Overview
13.10.3 Product Benchmarking
13.10.4 Strategic Outlook
13.11 Sinovac Biotech Ltd.
13.11.1 Company Snapshot
13.11.2 Company Overview
13.11.3 Financial Analysis
13.11.3.1 Net Revenue, 2016-2021
13.11.3.2 Gross Profit, 2016-2021
13.11.3.3 R&D, 2016-2021
13.11.4 Product Benchmarking
13.12 Valneva SE
13.12.1 Company Snapshot
13.12.2 Company Overview
13.12.3 Financial Analysis
13.12.3.1 Net Revenue, 2016-2021
13.12.4 Product Benchmarking
13.12.5 Strategic Outlook

14 Conclusion and Recommendations
14.1 Concluding Remarks from Visiongain
14.2 Recommendations for Market Players

List of Tables
Table 1 Global Anti-infective Vaccines Market Snapshot, 2022 & 2032 (US$ billion, CAGR %)
Table 2 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 3 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 4 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 5 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 6 Global Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 7 Bacterial Diseases Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 8 Viral Diseases Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 9 Global Anti-infective Vaccines Market Forecast by Product Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 10 Live/Attenuated Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 11 Major Whole Inactivated Virus COVID-19 Vaccine
Table 12 Inactivated Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 13 DNA Vaccines for Global COVID-19: Global Status
Table 14 DNA & Recombinant Vector Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 15 Others Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 16 Global Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million, AGR%, CAGR %)
Table 17 Hospital Pharmacy Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 18 Retail Pharmacy Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 19 Others Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 20 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 21 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 22 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 23 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 24 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 25 North America Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 26 North America Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 27 North America Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 28 North America Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 29 North America Anti-infective Vaccines Market Forecast by Product Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 30 North America Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million, AGR%, CAGR %)
Table 31 U.S Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 32 Canada Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 33 Europe Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 34 Europe Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 35 Europe Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 36 Europe Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 37 Europe Anti-infective Vaccines Market Forecast by Product Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 38 Europe Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million, AGR%, CAGR %)
Table 39 Germany Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 40 UK Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 41 France Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 42 Italy Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 43 Spain Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 44 Russia Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 45 Rest of Europe Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 46 Asia Pacific Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 47 Asia Pacific Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 48 Asia Pacific Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 49 Asia Pacific Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 50 Asia Pacific Anti-infective Vaccines Market Forecast by Product Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 51 Asia Pacific Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million, AGR%, CAGR %)
Table 52 Japan Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 53 China Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 54 India Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 55 Australia Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 56 Rest of Asia Pacific Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 57 Latin America Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 58 Latin America Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 59 Latin America Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 60 Latin America Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 61 Latin America Anti-infective Vaccines Market Forecast by Product Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 62 Latin America Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million, AGR%, CAGR %)
Table 63 Brazil Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 64 Mexico Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 65 Rest of Latin America Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 66 MEA Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 67 MEA Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 68 MEA Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 69 MEA Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 70 MEA Anti-infective Vaccines Market Forecast by Product Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 71 MEA Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million, AGR%, CAGR %)
Table 72 GCC Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 73 South Africa Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 74 MEA Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 75 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 76 AstraZeneca: Product Benchmarking
Table 77 AstraZeneca: Strategic Outlook
Table 78 Bavarian Nordic: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 Bavarian Nordic: Product Benchmarking
Table 80 Bavarian Nordic: Strategic Outlook
Table 81 BioDiem: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 BioDiem: Product Benchmarking
Table 83 CSL Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 84 CSL Limited: Product Benchmarking
Table 85 CSL Limited: Strategic Outlook
Table 86 Emergent BioSolutions Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 Emergent BioSolutions Inc.: Product Benchmarking
Table 88 Emergent BioSolutions Inc.: Strategic Outlook
Table 89 Evotec: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 Evotec: Product Benchmarking
Table 91 Evotec: Strategic Outlook
Table 92 Merck & Co, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 Merck & Co, Inc.: Product Benchmarking
Table 94 Merck & Co, Inc.: Strategic Outlook
Table 95 Mitsubishi Tanabe Pharma Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 Mitsubishi Tanabe Pharma Corporation: Product Benchmarking
Table 97 Mitsubishi Tanabe Pharma Corporation: Strategic Outlook
Table 98 Pfizer: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Pfizer: Product Benchmarking
Table 100 Pfizer: Strategic Outlook
Table 101 Serum Institute of India Pvt. Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 Serum Institute of India Pvt. Ltd.: Product Benchmarking
Table 103 Serum Institute of India Pvt. Ltd.: Strategic Outlook
Table 104 Sinovac Biotech Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Sinovac Biotech Ltd.: Product Benchmarking
Table 106 Valneva SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Valneva SE: Product Benchmarking
Table 108 Valneva SE: Strategic Outlook

List of Figures
Figure 1 Global Anti-infective Vaccines Market Segmentation
Figure 2 Global Anti-infective Vaccines Market Attractiveness Index by Region
Figure 3 Global Anti-infective Vaccines Market by Disease Type: Market Attractiveness Index
Figure 4 Global Anti-infective Vaccines Market by Product: Market Attractiveness Index
Figure 5 Global Anti-infective Vaccines Market by Distribution Channel: Market Attractiveness Index
Figure 6 Global Anti-infective Vaccines Market: Market Dynamics
Figure 7 Global COVID Impact Analysis: Anti-infective Vaccines Market Recovery Scenarios
Figure 8 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 9 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 10 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 11 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 12 Global Anti-infective Vaccines Market: Porter’s Five Forces Analysis
Figure 13 Global Anti-infective Vaccines Market: PEST Analysis
Figure 14 Global Anti-infective Vaccines Market Attractiveness Index by Disease Type
Figure 15 Global Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million)
Figure 16 Global Anti-infective Vaccines Market Share Forecast by Disease Type, 2022, 2027, 2032 (%)
Figure 17 Bacterial Diseases Market Forecast by Region, 2022-2032 (US$ million)
Figure 18 Bacterial Diseases Market Share Forecast by Region, 2022 & 2032 (%)
Figure 19 Viral Diseases Market Forecast by Region, 2022-2032 (US$ million)
Figure 20 Viral Diseases Market Share Forecast by Region, 2022 & 2032 (%)
Figure 21 Global Anti-infective Vaccines Market Attractiveness Index by Disease Type
Figure 22 Global Anti-infective Vaccines Market Forecast by Product, 2022-2032 (US$ million)
Figure 23 Global Anti-infective Vaccines Market Share Forecast by Product, 2022, 2027, 2032 (%)
Figure 24 Live/Attenuated Vaccines Market Forecast by Region, 2022-2032 (US$ million)
Figure 25 Live/Attenuated Vaccines Market Share Forecast by Region, 2022 & 2032 (%)
Figure 26 Inactivated Vaccines Market Forecast by Region, 2022-2032 (US$ million)
Figure 27 Inactivated Vaccines Market Share Forecast by Region, 2022 & 2032 (%)
Figure 28 DNA & Recombinant Vector Vaccines Market Forecast by Region, 2022-2032 (US$ million)
Figure 29 DNA & Recombinant Vector Vaccines Market Share Forecast by Region, 2022 & 2032 (%)
Figure 30 Others Market Forecast by Region, 2022-2032 (US$ million)
Figure 31 Others Market Share Forecast by Region, 2022 & 2032 (%)
Figure 32 Global Anti-infective Vaccines Market Attractiveness Index by Distribution Channel
Figure 33 Global Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million)
Figure 34 Global Anti-infective Vaccines Market Share Forecast by Distribution Channel, 2022, 2027, 2032 (%)
Figure 35 Hospital Pharmacy Market Forecast by Region, 2022-2032 (US$ million)
Figure 36 Hospital Pharmacy Market Share Forecast by Region, 2022 & 2032 (%)
Figure 37 Retail Pharmacy Market Forecast by Region, 2022-2032 (US$ million)
Figure 38 Retail Pharmacy Market Share Forecast by Region, 2022 & 2032 (%)
Figure 39 Others Market Forecast by Region, 2022-2032 (US$ million)
Figure 40 Others Market Share Forecast by Region, 2022 & 2032 (%)
Figure 41 Global Anti-infective Vaccines Market Forecast by Region 2022, 2027, 2032 (Revenue, CAGR %)
Figure 42 Global Anti-infective Vaccines Market Share Forecast by Region 2022, 2027, 2032(%)
Figure 43 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Figure 44 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 45 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 46 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 47 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 48 North America Anti-infective Vaccines Market Attractiveness Index
Figure 49 North America Anti-infective Vaccines Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 50 North America Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million)
Figure 51 North America Anti-infective Vaccines Market Share Forecast by Country, 2022 & 2032 (%)
Figure 52 North America Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million)
Figure 53 North America Anti-infective Vaccines Market Share Forecast by Disease Type, 2022 & 2032 (%)
Figure 54 North America Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million)
Figure 55 North America Anti-infective Vaccines Market Share Forecast by Bacterial Diseases, 2022 & 2032 (%)
Figure 56 North America Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million)
Figure 57 North America Anti-infective Vaccines Market Share Forecast by Viral Diseases, 2022 & 2032 (%)
Figure 58 North America Anti-infective Vaccines Market Forecast by Product, 2022-2032 (US$ million)
Figure 59 North America Anti-infective Vaccines Market Share Forecast by Product, 2022 & 2032 (%)
Figure 60 North America Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million)
Figure 61 North America Anti-infective Vaccines Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 62 U.S. Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 63 Canada Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 64 Europe Anti-infective Vaccines Market Attractiveness Index
Figure 65 Europe Anti-infective Vaccines Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 66 Europe Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million)
Figure 67 Europe Anti-infective Vaccines Market Share Forecast by Country, 2022 & 2032 (%)
Figure 68 Europe Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million)
Figure 69 Europe Anti-infective Vaccines Market Share Forecast by Disease Type, 2022 & 2032 (%)
Figure 70 Europe Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million)
Figure 71 Europe Anti-infective Vaccines Market Share Forecast by Bacterial Diseases, 2022 & 2032 (%)
Figure 72 Europe Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million)
Figure 73 Europe Anti-infective Vaccines Market Share Forecast by Viral Diseases, 2022 & 2032 (%)
Figure 74 Europe Anti-infective Vaccines Market Forecast by Product, 2022-2032 (US$ million)
Figure 75 Europe Anti-infective Vaccines Market Share Forecast by Product, 2022 & 2032 (%)
Figure 76 Europe Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million)
Figure 77 Europe Anti-infective Vaccines Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 78 Germany Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 79 UK Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 80 France Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 81 Italy Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 82 Spain Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 83 Russia Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 84 Rest of Europe Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 85 Asia Pacific Anti-infective Vaccines Market Attractiveness Index
Figure 86 Asia Pacific Anti-infective Vaccines Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 87 Asia Pacific Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million)
Figure 88 Asia Pacific Anti-infective Vaccines Market Share Forecast by Country, 2022 & 2032 (%)
Figure 89 Asia Pacific Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million)
Figure 90 Asia Pacific Anti-infective Vaccines Market Share Forecast by Disease Type, 2022 & 2032 (%)
Figure 91 Asia Pacific Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million)
Figure 92 Asia Pacific Anti-infective Vaccines Market Share Forecast by Bacterial Diseases, 2022 & 2032 (%)
Figure 93 Asia Pacific Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million)
Figure 94 Asia Pacific Anti-infective Vaccines Market Share Forecast by Viral Diseases, 2022 & 2032 (%)
Figure 95 Asia Pacific Anti-infective Vaccines Market Forecast by Product, 2022-2032 (US$ million)
Figure 96 Asia Pacific Anti-infective Vaccines Market Share Forecast by Product, 2022 & 2032 (%)
Figure 97 Asia Pacific Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million)
Figure 98 Asia Pacific Anti-infective Vaccines Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 99 Japan Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 100 China Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 101 India Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 102 Australia Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 103 Rest of Asia Pacific Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 104 Latin America Anti-infective Vaccines Market Attractiveness Index
Figure 105 Latin America Anti-infective Vaccines Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 106 Latin America Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million)
Figure 107 Latin America Anti-infective Vaccines Market Share Forecast by Country, 2022 & 2032 (%)
Figure 108 Latin America Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million)
Figure 109 Latin America Anti-infective Vaccines Market Share Forecast by Disease Type, 2022 & 2032 (%)
Figure 110 Latin America Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million)
Figure 111 Latin America Anti-infective Vaccines Market Share Forecast by Bacterial Diseases, 2022 & 2032 (%)
Figure 112 Latin America Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million)
Figure 113 Latin America Anti-infective Vaccines Market Share Forecast by Viral Diseases, 2022 & 2032 (%)
Figure 114 Latin America Anti-infective Vaccines Market Forecast by Product, 2022-2032 (US$ million)
Figure 115 Latin America Anti-infective Vaccines Market Share Forecast by Product, 2022 & 2032 (%)
Figure 116 Latin America Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million)
Figure 117 Latin America Anti-infective Vaccines Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 118 Brazil Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 119 Mexico Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 120 Rest of Latin America Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 121 MEA Anti-infective Vaccines Market Attractiveness Index
Figure 122 MEA Anti-infective Vaccines Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 123 MEA Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million)
Figure 124 MEA Anti-infective Vaccines Market Share Forecast by Country, 2022 & 2032 (%)
Figure 125 MEA Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million)
Figure 126 MEA Anti-infective Vaccines Market Share Forecast by Disease Type, 2022 & 2032 (%)
Figure 127 MEA Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million)
Figure 128 MEA Anti-infective Vaccines Market Share Forecast by Bacterial Diseases, 2022 & 2032 (%)
Figure 129 MEA Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million)
Figure 130 MEA Anti-infective Vaccines Market Share Forecast by Viral Diseases, 2022 & 2032 (%)
Figure 131 MEA Anti-infective Vaccines Market Forecast by Product, 2022-2032 (US$ million)
Figure 132 MEA Anti-infective Vaccines Market Share Forecast by Product, 2022 & 2032 (%)
Figure 133 MEA Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million)
Figure 134 MEA Anti-infective Vaccines Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 135 GCC Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 136 South Africa Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 137 Rest of MEA Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 138 AstraZeneca: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 139 AstraZeneca: Regional Market Shares, 2021
Figure 140 AstraZeneca: Gross Profit, 2016-2021 (US$ million, AGR %)
Figure 141 AstraZeneca: R&D, 2016-2021 (US$ million, AGR %)
Figure 142 Bavarian Nordic: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 143 Bavarian Nordic: Regional Market Shares, 2021
Figure 144 Bavarian Nordic: Gross Profit, 2016-2021 (US$ million, AGR %)
Figure 145 Bavarian Nordic: R&D, 2016-2021 (US$ million, AGR %)
Figure 146 CSL Limited: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 147 CSL Limited: Regional Market Shares, 2021
Figure 148 CSL Limited: Gross Profit, 2016-2021 (US$ million, AGR %)
Figure 149 CSL Limited: R&D, 2016-2021 (US$ million, AGR %)
Figure 150 Emergent BioSolutions Inc.: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 151 Emergent BioSolutions Inc.: Gross Profit, 2016-2021 (US$ million, AGR %)
Figure 152 Emergent BioSolutions Inc.: R&D, 2016-2021 (US$ million, AGR %)
Figure 153 Evotec: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 154 Evotec: Regional Market Shares, 2021
Figure 155 Evotec: Gross Profit, 2016-2021 (US$ million, AGR %)
Figure 156 Evotec: R&D, 2016-2021 (US$ million, AGR %)
Figure 157 Merck & Co, Inc.: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 158 Merck & Co, Inc.: Regional Market Shares, 2021
Figure 159 Merck & Co, Inc.: Gross Profit, 2016-2021 (US$ million, AGR %)
Figure 160 Merck & Co, Inc.: R&D, 2016-2021 (US$ million, AGR %)
Figure 161 Pfizer: Net Revenue, 2016-2021 (US$ million, AGR%)
Figure 162 Pfizer: Regional Market Shares, 2021
Figure 163 Pfizer: Gross Profit, 2016-2021 (US$ million, AGR%)
Figure 164 Pfizer: R&D, 2016-2021 (US$ million, AGR%)
Figure 165 Sinovac Biotech Ltd.: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 166 Sinovac Biotech Ltd.: Gross Profit, 2016-2021 (US$ million, AGR %)
Figure 167 Sinovac Biotech Ltd.: R&D, 2016-2021 (US$ million, AGR %)
Figure 168 Valneva SE: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 169 Global Anti-infective Vaccines Market Forecast by Region 2022, 2027, 2032 (Revenue, CAGR %)
Figure 170 Global Anti-infective Vaccines Market Share Forecast by Region 2022, 2027, 2032 (%)

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（通信回線）の最新刊レポート

Visiongain社の医薬・化学品分野での最新刊レポート

本レポートと同じKEY WORD（vaccine）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

Visiongain社はどのような調査会社ですか?

英国の調査会社ヴィジョンゲイン社（Visiongain）は、通信とエネルギーのほか、自動車や化学・医薬品、金属など、広範な市場を対象に調査を行っています。自動車市場については、市場全般に関する調査のほ... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。